Deferasirox for up to 3 years leads to continued improvement of myocardial T2* in patients with β-thalassemia major.

@article{Pennell2012DeferasiroxFU,
  title={Deferasirox for up to 3 years leads to continued improvement of myocardial T2* in patients with β-thalassemia major.},
  author={Dudley J. Pennell and John B. Porter and Maria Domenica Cappellini and Lee Lee Chan and Amal M El-Beshlawy and Yeşim Aydinok and Hishamshah Mohamad Ibrahim and Chi K Li and Vip Viprakasit and Mohsen Saleh Elalfy and Antonis Kattamis and Gillian L F Smith and Dany Habr and Gabor Domokos and Bernard Roubert and Ali Asghar Taher},
  journal={Haematologica},
  year={2012},
  volume={97 6},
  pages={842-8}
}
BACKGROUND Prospective data on cardiac iron removal are limited beyond one year and longer-term studies are, therefore, important. DESIGN AND METHODS Seventy-one patients in the EPIC cardiac substudy elected to continue into the 3(rd) year, allowing cardiac iron removal to be analyzed over three years. RESULTS Mean deferasirox dose during year 3 was 33.6 ± 9.8 mg/kg per day. Myocardial T2*, assessed by cardiovascular magnetic resonance, significantly increased from 12.0 ms ± 39.1% at… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 50 extracted citations

Similar Papers

Loading similar papers…